Mr. Posard held influential leadership roles with market leading companies including Illumina, Trovagene, Biosite/Alere and Gen-Probe. Mr. Posard was key in leading Illumina to its first $1B in revenue and was Senior Vice President responsible for its entry into the clinical, forensics and consumer genomics markets. Mr. Posard holds a B.A. degree in Quantitative Economics and Decision Science from the University of California, San Diego and currently serves as a board member for Halozyme Therapeutics, SlipChip Corporation, Omicia and Envision Genomics.
DermTech is a commercial stage molecular dermatology company developing non-invasive gene expression tests to aid the clinical diagnosis of skin cancer and inflammatory skin conditions. DermTech operates a CLIA licensed and CAP accredited laboratory in the company's La Jolla, CA headquarters. DermTech's technology allows the analysis of skin biopsy samples collected non-invasively using an adhesive patch. DermTech provides highly accurate, objective information to the physicians to improve care and reduce costs. Current dermatologic diagnosis is primarily based on subjective visual pattern recognition that is prone to error and results in a substantial number of unnecessary surgical procedures. For additional information visit: www.dermtech.com.
Sarah Dennison, MBA
VP of Marketing
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dermtech-announces-expansion-of-board-of-directors-and-commercial-team-300294991.html
SOURCE DermTech, Inc.